Breaking News

NovaSAID, Cadila Enter Drug Development Pact

By Kristin Brooks | January 10, 2014

To pursue new treatments for inflammation and pain

NovaSAID AB, a Karolinska Development portfolio company, and Cadila Pharmaceuticals have entered a strategic partnership to develop new treatments for inflammation and pain in conditions such as rheumatoid arthritis. The companies will collaborate on preclinical and clinical development of drug candidates developed by NovaSAID, which will be conducted at Cadila’s facility in Ahmedabad, India.
 
Cadila will have commercialization rights in India, the Middle East and Africa and the two companies will share sales in all other countries. Cadila will be responsible for all costs associated with the program through Phase II.
 
“This partnership gives the shareholders of NovaSAID the opportunity to take the company forward with great resources and no further costs. Cadila’s drug development expertise matched with NovaSAID’s scientific excellence provides a solid platform for the further development of these novel drug candidates. If successfully developed, valuable deals could be signed in major territories such as the US and Europe to the benefit for Karolinska Development’s shareholders,” said Dr. Torbjörn Bjerke, chief executive officer of Karolinska Development.

blog comments powered by Disqus
  • Cold Chain Packaging Trends

    Cold Chain Packaging Trends

    Kristin Brooks, Contract Pharma||February 4, 2016
    Susan Li of UPS discusses supply chain trends, challenges, and packaging innovations

  • Packaging Equipment Trends Preview

    Packaging Equipment Trends Preview

    Kristin Brooks, Contract Pharma||January 26, 2016
    Christian Treitel of Bosch Packaging Technology discusses trends and capabilities

  • Filings Update

    Filings Update

    December 1, 2015
    Roche, Pfizer, Janssen, BMS and more

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016